Veeva Gives Away Its AI Agents and Bills the Seat Migration
Barron's calls Veeva the plumbing of AI medicine and analyst coverage pitches 30% upside on a stock already up 27.87% this year. But Veeva's own releases show the flagship agent ships free and the marquee win had no disclosed value; the billable business is a CRM migration with a 2029 deadline.
Vincent Jiang · 3 min read
The plumbing call on a stock already up 28%
Barron's ended September with a stock pick titled "AI Will Revolutionize Medicine. This Company Provides the Plumbing" 1. The bull math sits elsewhere: analyst coverage on 1 October framed VEEV, trading near $285, as offering up to 30% upside over the next 12 months 11. The tape already moved. The stock closed 30 September at $285.45, up 2.47% on the day and 27.87% for the year, against an average target of $297.30 from 29 analysts 3. Wells Fargo's Stan Berenshteyn carries Overweight at $330 311, and Asian trading coverage tied the move to the week's AI announcements 2.
Targets sit above a stock that already ran 28% this year
Data
| Veeva share price and targets | |
|---|---|
| Close, 30 Sep | $285.45 |
| Average target (29 analysts) | $297.3 |
| Wells Fargo target | $330 |
The flagship agent has no price on it
The re-rating rides on announcements with no revenue line. Study Builder Agent, unveiled 24 September, configures clinical data capture and quality systems straight from a study protocol in as little as one day. It requires no additional license: it ships inside Veeva EDC to early adopters in December 4.
Delivered as a Claude Cowork plugin, the agent's availability follows Anthropic's supported regions: the US, Europe, Japan and India. Mainland China, where Anthropic restricts its models, is out; Veeva Clinical Data CTO Drew Garty says study configuration there is not typically done by local teams anyway 5. The engine is rented from a company whose IPO prospectus points to a valuation above $2 trillion 6.
The week's other headline has no number either
Servier's OpenData standardization across more than 80 countries went out as a paid release with no contract value 7. Veeva's own promotion leans on the claim that the industry "fails to scale 89% of AI initiatives due to data challenges" 7. A foundation-governed French drugmaker adopting the data layer is a real win; it is just not yet a number.
What Veeva bills is the migration underneath
Subscriptions are 84% of sales 3. The billable machine is Vault CRM: more than 190 live customers and commitments from 14 of the top 20 biopharmas, including Amgen, Biogen, Eli Lilly and Regeneron 8, up from 125 live in March 9.
That same month, Veeva pulled legacy CRM's end-of-support forward from September 2030 to December 2029 9, turning the installed base into a scheduled migration. Revenue does the quiet work: $927.96M in the quarter ended 31 July, up 17.6% year over year, the eighth straight quarterly rise on file 10.
Veeva's revenue has risen in each of the last eight reported quarters
Data
| Quarterly revenue | |
|---|---|
| Q3 '24 | $699.21M |
| Q4 '24 | $720.89M |
| Q1 '25 | $759.04M |
| Q2 '25 | $789.08M |
| Q3 '25 | $811.24M |
| Q4 '25 | $835.95M |
| Q1 '26 | $882.95M |
| Q2 '26 | $927.96M |
December decides the agent story
The bull case is not nothing: full-year guidance was raised toward $3.7 billion, a third upward revision this year, and management targets a $6 billion run rate by 2030 11. But the agents drawing the headlines are, in effect, retention spend, given away to defend the seats they run on. The rule the re-rating has to pass: the price stands on the seats that must move before December 2029, not on agents that ship free in December. Veeva is giving away the robots and charging for the moving vans.
Deepdive
AI-generated from this story and its cited sources. Not investment advice.
